27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
The analysts elaborated that the pipeline includes an expected increase in sales of Keytruda, a melanoma treatment drug used on President Jimmy Carter, which helped him become cancer free.
"Clinics around the country were hearing, 'I want what Jimmy Carter had,'" said Dr. Patrick Ott, a melanoma specialist at the Dana-Farber Cancer Institute in Boston.
To its benefit, Keytruda has been approved for additional indications.
Related Link: Barclays Raises Target On Merck, Lowers Target On Bristol-Myers
The recent European approval of Hep C drug Zepatier in all 28 EU member states, is seen as revenue driver for the second half of 2016 as well, according to Argus.
Argus reiterated its Buy rating on Merck with a target price of $65.
At time of writing, Merck was down 1.99 percent at $61.95.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!